When these UCART19 cells were infused into two infants with r/r CD19+ B cell acute lymphoblastic leukemia, molecular remissions were achieved within 28 days, and UCART19 cells persisted during the course of therapy. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.